FDA Approves Janssen’s Imaavy for Rare Blood Disorder
SILVER SPRING, MARYLAND, Aug 26, 2026 The U.S. Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu) injection for...
fast track
Advertisement
Protagenic Advances PT00114 Toward FDA IND Submission
New York, New York, USA, August 20, 2026 Protagenic Therapeutics, a clinical-stage biopharmaceutical company developing peptide-based treatments for stress-related...
Werewolf Therapeutics and Ambros Announce $150M Merger
Waltham, Massachusetts, USA, and San Diego, California, USA, August 21, 2026 Werewolf Therapeutics and Ambros Therapeutics have announced a...
Acurx Advances Ibezapolstat Toward Phase 3 Development
Staten Island, New York, August 17, 2026 Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing antibiotics for difficult-to-treat bacterial...
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy Program
Warren, New Jersey, August 12, 2026 PTC Therapeutics announced that it was selected as the winning bidder to acquire...
Advertisements
Definium Therapeutics Reports Positive Phase 3 GAD Results
NEW YORK, August 12, 2026 Definium Therapeutics, Inc. announced positive topline results from the Phase 3 Voyage study evaluating...
Alterity Expands ATH434 Potential in Neurodegenerative Disease
MELBOURNE, Australia and SAN FRANCISCO, USA, August 12, 2026 Alterity Therapeutics Limited announced that the U.S. Patent and Trademark...
Annexon Expands Phase 3 ARCHER II Trial in Geographic Atrophy
BRISBANE, Calif., August 12, 202 Annexon, Inc. announced the expansion of its ongoing Phase 3 ARCHER II trial evaluating...
LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer
BOTHELL, Wash., August 12, 2026 LeonaBio, Inc. announced that its lead investigational therapy lasofoxifene will be featured in multiple...
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
Advertisement
